Vitamin K2 MK-4 vs MK-7: Which Form Actually Fits Your Goal?
Most people buying vitamin K2 don't realize they're choosing between two compounds with meaningfully different half-lives, tissue targets, and research profiles. The form matters more than the dose.
Why the Form of K2 Changes Everything
Vitamin K2 activates proteins that direct calcium into bones and away from arterial walls. The two most studied forms, MK-4 and MK-7, both do this, but they behave differently once inside your body.
MK-4 (menatetrenone) is a short-chain menaquinone. It clears your bloodstream within hours. MK-7 (menaquinone-7) is a long-chain form derived primarily from natto (fermented soybeans). It has a half-life of roughly 72 hours, meaning a single daily dose keeps circulating levels elevated throughout the day.
That pharmacokinetic difference drives most of the practical distinctions between the two.
The two key proteins K2 activates are osteocalcin (which binds calcium into bone matrix) and Matrix Gla Protein, or MGP (which inhibits calcium from depositing in soft tissue). Both forms activate these proteins, but the evidence base behind each skews toward different applications.
MK-4 vs MK-7: A Direct Comparison
| Feature | MK-4 | MK-7 |
|---|---|---|
| Half-life | 1–2 hours | ~72 hours |
| Typical clinical dose | 1,500 mcg (1.5 mg) per day | 90–200 mcg per day |
| Primary research area | Bone density, fracture risk | Arterial calcification, cardiovascular markers |
| Common source | Synthetic (animal tissue in food) | Natto, fermented foods |
| Dosing frequency | Often split into 3 doses | Once daily |
| Absorption | Fat-soluble, requires dietary fat | Fat-soluble, requires dietary fat |
The dose gap is significant. MK-4 studies that show bone benefits typically use 1,500 mcg daily, which is far above what most supplements provide. MK-7 produces measurable effects on carboxylated osteocalcin at doses as low as 90 mcg daily, according to research reviewed by the NIH Office of Dietary Supplements.
Which Form for Which Goal?
Bone Density and Fracture Risk
MK-4 has the longer clinical track record for bone outcomes. Japanese trials using 1,500 mcg daily showed reductions in vertebral fracture risk in postmenopausal women. The mechanism is direct activation of osteocalcin, which anchors calcium into the bone matrix.
MK-7 also supports bone density, but the evidence base is smaller. A 2013 randomized controlled trial published in Osteoporosis International found that 180 mcg of MK-7 daily improved bone strength indices in postmenopausal women over three years. Both forms are relevant here. MK-7 is more practical for most people because of the lower dose and once-daily convenience.
Arterial and Cardiovascular Health
MK-7 is the more studied form for arterial calcification. MGP, the protein that prevents calcium from hardening arterial walls, requires K2 to become carboxylated (active). MK-7's longer half-life means MGP activation is sustained across 24 hours rather than spiking and dropping.
If cardiovascular calcification risk is your primary concern, MK-7 at 100–200 mcg daily is the better-supported choice.
Pairing K2 with D3
This is where K2's role becomes most relevant for most adults. Vitamin D3 increases calcium absorption from the gut. Without adequate K2, that extra circulating calcium has no reliable guide directing it into bone rather than soft tissue. The two work as a pair. If you're already using Elm & Rye's Vitamin D3 supplement, adding K2 MK-7 is the logical next step for anyone focused on bone or cardiovascular health.
For men over 40 specifically, this pairing becomes more pressing as bone remodeling slows and arterial stiffness increases. Our breakdown of essential vitamins for men over 40 covers this combination in more detail.
The Reality Check
Neither form of K2 produces dramatic short-term changes you'll feel. Bone density shifts take months to measure. Arterial calcification progresses over years. Expect gradual, cumulative benefits over 3–12 months of consistent use, not a noticeable effect in week two.
Who should be cautious:
- Anyone taking warfarin (Coumadin) or other vitamin K antagonist anticoagulants. K2 directly affects clotting factor activation. Do not add K2 without physician oversight if you're on blood thinners.
- People with hyperparathyroidism or conditions affecting calcium metabolism should consult a doctor before supplementing.
- MK-7 from natto sources may cause issues for people with soy allergies, depending on the extraction process.
K2 is fat-soluble, so take it with a meal that contains dietary fat. Taking it on an empty stomach reduces absorption significantly.
My take: I lean toward MK-7 at 100–200 mcg daily for most adults because the once-daily dosing matches how people actually take supplements, and the sustained half-life means you're not chasing peak serum levels throughout the day. The lower absolute dose also makes it easier to pair with D3 without overshooting K2 intake, which is why that pairing is what I'd prioritize for anyone already managing a D3 protocol.
The Bottom Line
MK-4 has the stronger bone-specific clinical history at high doses (1,500 mcg daily), while MK-7 offers more practical dosing (90–200 mcg once daily) with solid evidence for both bone and arterial health. For most adults, MK-7 is the better daily-use form, especially when paired with D3.
---
FAQ
What is the difference between MK-4 and MK-7?
MK-4 and MK-7 are both forms of vitamin K2 that activate calcium-directing proteins in the body. MK-4 clears the bloodstream within hours and requires higher doses (around 1,500 mcg daily), while MK-7 has a roughly 72-hour half-life and works at much lower doses (90–200 mcg daily).
Can I take vitamin K2 and D3 together?
Yes, and most practitioners recommend it. Vitamin D3 increases calcium absorption, and K2 activates the proteins that direct that calcium into bone rather than soft tissue. Take both with a fat-containing meal for best absorption.
Is MK-7 safe for long-term daily use?
MK-7 is generally well-tolerated at doses up to 200 mcg daily in healthy adults. The main exception is anyone taking warfarin or other vitamin K antagonist medications, where K2 supplementation can interfere with anticoagulation therapy and requires medical supervision.